Showing results (2111-2120 of 2,436) with videos related to

Sort By:
Pageof 244
BMC Medical Genetics|January 22, 2008
Genetic loci linked to type 1 diabetes and multiple sclerosis families in SardiniaMaristella Pitzalis, Patrizia Zavattari, Raffaele Murru, et al.
Tumori|March 19, 2017
Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologistsCarlo Furlan, Stefano Arcangeli, Michele Avanzo, et al.
Science (New York, N.Y.)|September 1, 2022
GnRH replacement rescues cognition in Down syndromeMaria Manfredi-Lozano, Valerie Leysen, Michela Adamo, et al.
Journal of Translational Medicine|September 30, 2022
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 studySara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
Frontiers in Oncology|October 10, 2022
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysisSara Elena Rebuzzi, Alessio Signori, Marco Stellato, et al.
Pathology|March 29, 2021
The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosisSonja Klebe, Yukio Nakatani, Katalin Dobra, et al.
Nature Communications|February 8, 2024
Targeting DNA2 overcomes metabolic reprogramming in multiple myelomaNatthakan Thongon, Feiyang Ma, Natalia Baran, et al.
Scientific Reports|June 17, 2026
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysisBrigida Anna Maiorano, Giandomenico Roviello, Alessandro Rizzo, et al.
Genome Research|April 29, 2015
Exome sequencing reveals pathogenic mutations in 91 strains of mice with Mendelian disordersHeather Fairfield, Anuj Srivastava, Guruprasad Ananda, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2025
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 studyPhilipp Mandel, Daniel Groener, Giulia Follacchio, et al.
Pageof 244